Next Article in Journal
Metabolic Impact of Anticancer Drugs Pd2Spermine and Cisplatin on the Brain of Healthy Mice
Next Article in Special Issue
Pharmacogene Variants Associated with Liver Transplant in a Twelve-Year Clinical Follow-Up
Previous Article in Journal
Oligonucleotide Therapeutics: From Discovery and Development to Patentability
Previous Article in Special Issue
FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 14
Issue 2
10.3390/pharmaceutics14020261
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Association of P450 Oxidoreductase Gene Polymorphism with Tacrolimus Pharmacokinetics in Renal Transplant Recipients: A Systematic Review and Meta-Analysis

by
Da-Hoon Lee
1,
Hana Lee
2,
Ha-Young Yoon
1,
Jeong Yee
1,* and
Hye-Sun Gwak
1,*
1
College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea
2
Graduate School of Clinical Biohealth, Ewha Womans University, Seoul 03760, Korea
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2022, 14(2), 261; https://doi.org/10.3390/pharmaceutics14020261
Submission received: 4 January 2022 / Revised: 20 January 2022 / Accepted: 20 January 2022 / Published: 22 January 2022
(This article belongs to the Special Issue Association Studies in Clinical Pharmacogenetics)
Browse Figures
Versions Notes

Abstract

:
There are conflicting results regarding the effect of the P450 oxidoreductase (POR) *28 genotype on the tacrolimus (TAC) pharmacokinetics (PKs) during the early post-transplantation period in adult renal transplant recipients. Thus, we characterized the impact of POR*28 on TAC PKs. We conducted a systematic review on the association between POR*28 and PKs of TAC in adult renal transplant recipients. Structured searches were conducted using PubMed, Web of Science, and Embase. TAC standardized trough concentration (ng/mL per mg/kg) data were extracted. Mean differences (MD) and their corresponding 95% confidence intervals (CIs) were used to identify the differences between the POR*28 genotype and PKs of TAC. The subgroup analysis was conducted according to CYP3A5 expression status. Six studies (n = 1061) were included. TAC standardized trough concentrations were significantly lower in recipients with the POR*28 allele compared to recipients with POR*1/*1 (MD: 8.30 ng/mL per mg/kg; 95% CI: 1.93, 14.67; p = 0.01). In the subgroup analysis, TAC standardized trough concentrations were lower for subjects who were POR*28 carriers than those who were POR*1/*1 in CYP3A5 expressers (MD: 20.21 ng/mL per mg/kg; 95% CI: 16.85, 23.56; p < 0.00001). No significant difference between POR*28 carriers and POR*1/*1 was found in the CYP3A5 non-expressers. The results of our meta-analysis demonstrated a definite correlation between the POR*28 genotype and PKs of TAC. Patients carrying the POR*28 allele may require a higher dose of TAC to achieve target levels compared to those with POR*1/*1, especially in CYP3A5 expressers.

Graphical Abstract

1. Introduction

Tacrolimus (TAC), one of the calcineurin inhibitors, is commonly used as an immunosuppressant to prevent acute organ rejection after kidney transplantation [1]. TAC has a narrow therapeutic index and wide interindividual pharmacokinetic (PK) variability. Thus, TAC administration requires therapeutic drug monitoring (TDM) to enhance efficacy and to avoid side effects [1,2,3,4]. Although TDM is widely practiced, some patients are exposed to sub- or supra-therapeutic concentrations of TAC, thereby increasing their risk of acute organ rejection or toxicity within a week after transplantation [5].
TAC is metabolized by cytochrome P450 (CYP), especially CYP3A5 [6]. CYP3A5*3 (c.219-237A>G; rs776746) is a critical predictor of CYP3A5 activity [7,8], and several studies reported that CYP3A5 non-expressers (CYP3A5*3/*3) are related to decreased metabolizing functions and higher TAC trough concentrations compared with CYP3A5 expressers (CYP3A5*1/*1 or CYP3A5*1/*3) [9,10,11,12].
Recently, further attention has been given to P450 oxidoreductase (POR), which transfers electrons from nicotinamide-adenine-dinucleotide phosphate-oxidase to CYP enzymes, inducing CYP expression and affecting TAC metabolism [13,14]. Among several single nucleotide polymorphisms (SNPs) of POR, the most common variant is POR*28 (c.1508 C>T, rs1057868). According to an in vitro study, this SNP was associated with increased CYP activity, including CYP1A2, CYP2C19, CYP3A4, and CYP3A5 [15]. Previous studies have investigated the role of POR*28 in the PKs of TAC and reported that patients carrying POR*28 exhibited lower trough concentrations of TAC and required higher TAC doses than wild-type patients (POR*1/*1) [16,17,18]. However, the results of previous studies are conflicting due to their small sample sizes. Therefore, we conducted a systematic review and meta-analysis of the existing studies to determine the effects of POR*28 on TAC trough concentrations in renal transplant patients.

2. Materials and Methods

2.1. Search Strategy and Study Selection

This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [19]. We performed a comprehensive search of three electronic databases (PubMed, Web of Science, and Embase) on 16 July 2021 using the following search terms: (tacrolimus OR FK506 OR FK-506 OR (calcineurin inhibitor) OR Prograf OR immunosuppress*) AND ((kidney transplant*) OR (kidney graft*) OR (kidney allograft*) OR (renal transplant*) OR (renal graft*) OR (renal allograft*)) AND (POR OR (p450 oxidoreductase) OR (cytochrome p450 oxidoreductase) OR CYPOR) AND (polymorph* OR variant* OR mutation* OR genotyp* OR phenotyp* OR haplotyp* OR SNP OR rs1057868 OR Ala503Val OR A503V) (Table 1).
Studies were selected if (1) the studies focused on the effects of the POR*28 genotype on renal transplant patients receiving TAC; (2) the studies had TAC PK data expressed as standardized trough concentration (ng/mL per mg/kg); and (3) the articles were published in English. Standardized trough concentration was determined as the concentration adjusted by the dose per body weight. Studies were excluded if they were (1) abstracts, reviews, editorials, or letters; (2) in vitro or in vivo studies; (3) studies performed on pediatric patients; or (4) studies from which we were unable to extract outcome data.
After removing duplicate studies, two authors independently excluded irrelevant studies by reviewing the titles and abstracts. Then, full-text articles were assessed for inclusion. Any inconsistencies were resolved by consensus between the two authors.

2.2. Data Extraction and Study Quality Assessment

Two reviewers independently extracted data using a preconceived data extraction spreadsheet. The following information was included: name of the first author, publication year, ethnicity, patient numbers, percentage of males, mean age, mean body weight, follow-up day, TAC initial dose, target trough level, concomitant drugs, and method of genotyping and quantification. Two reviewers assessed the study’s quality using the Newcastle–Ottawa scale (NOS) tool [20]. The NOS tool is based on three domains: the selection of exposed and unexposed subjects (0–4 points), comparability of study groups (0–2 points), and outcome assessment (0–3 points). In terms of comparability, if CYP3A5 expression and age were adjusted for the analysis, we rated them with 1 point for each.

2.3. Statistical Analysis

Mean differences (MD) and their corresponding 95% confidence intervals (CIs) were used to identify the differences between the POR*28 genotype and PKs of TAC, and the Z-test was performed to detect the statistically significant differences between two groups. To calculate pooled estimates, we extracted the mean and standard deviation. If the studies only reported the median and interquartile range, the formulas by Wan et al. [21] were used to estimate the mean and standard deviation. Data presented as log-transformed mean and standard deviation were converted to the raw scale using the methodology of Higgins et al. [22].
We assessed the heterogeneity across studies using the chi-square test and I2 statistics [23], and I2 > 50% was regarded as indicating significant heterogeneity. The fixed-effect model was used if there was no significant heterogeneity; otherwise, the random-effects model was used. When we confirmed heterogeneity, a sensitivity analysis was conducted by omitting each study in turn to assess the influence of individual studies. To detect publication bias, Begg’s rank correlation test and Egger’s regression test were performed using R Studio software (version 3.6.0; R Foundation for Statistical Computing, Vienna, Austria) [24,25]. As the effects of POR*28 can depend on the expression status of CYP3A5, a subgroup analysis was conducted according to CYP3A5 expression status. The meta-analysis was performed using Review Manager 5.4 (The Cochrane Collaboration, Copenhagen, Denmark). Statistical significance was defined as a p-value < 0.05.

3. Results

Our initial search yielded 586 studies, 501 of which remained after duplicates were removed. After excluding 451 articles based on their titles and abstracts, we assessed the full text of 50 studies. Among them, 44 studies were excluded for the following reasons: evaluating other genotypes (n = 20), not having concentration data with adjustment by body weight (n = 11), not an original article (n = 6), evaluating other outcomes (n = 5), and not able to extract data (n = 2). Finally, six studies [26,27,28,29,30,31] involving 1061 patients were included in the meta-analysis (Figure 1). The characteristics of these studies are summarized in Table 2. The studies were published between 2014 and 2018, and all were cohort studies. Four of the six studies were conducted with Asian populations, one with Caucasians, and the other with multiethnic groups. The mean age of the patients was 43.3 years (range 40.0–49.5). Quality scores evaluated using the NOS ranged from 7 to 9.
The results of a meta-analysis investigating POR*28 and standardized trough concentrations of TAC are shown in Figure 2. POR*28 carriers showed a 8.30 ng/mL per mg/kg lower concentration of TAC when compared with POR*1/*1 carriers (95% CI: 1.93, 14.67; p = 0.01; I2 = 55%). The funnel plot was asymmetrical (Figure 3), and Begg’s test and Egger’s test indicated no evidence of publication bias (p = 0.573 and p = 0.293, respectively). In the sensitivity analysis, the exclusion of Liu et al. led to a loss of statistical significance (Table 3).
Five studies reported the influence of the POR*28 genotype on the standardized trough concentrations of TAC according to CYP3A5 expression status [26,27,29,30,31]. There were 270 CYP3A5 expressers (CYP3A5*1/*1 or *1/*3) and 550 CYP3A5 non-expressers (CYP3A5*3/*3). In the CYP3A5 expressing subgroup, the TAC standardized trough concentration was 20.21 ng/mL per mg/kg lower for POR*28 carriers than for POR*1/*1 carriers (95% CI: 16.85, 23.56; p < 0.00001; I2 = 50%; Figure 4a). However, in the CYP3A5 non-expressing subgroup, POR*28 was not associated with the TAC standardized trough concentration (MD: 4.12 ng/mL per mg/kg, 95% CI: −9.11, 0.86; p = 0.1; I2 = 0%; Figure 4b).

4. Discussion

This is the first meta-analysis investigating the association between the POR*28 polymorphism and the standardized initial trough concentration of TAC in adult renal transplant recipients. The results showed that POR*28 carriers had a lower standardized trough concentration of TAC when compared with POR*1/*1 carriers. This association was increased in CYP3A5 expressers; however, POR*28 did not affect the TAC concentration in CYP3A5 non-expressers.
POR*28, a missense variant of POR, is the most common variant observed in about 28% of all alleles [32]. This variant is present in the flavin adenine dinucleotide (FAD) binding site, thereby affecting POR and CYP interactions [33]. In vitro studies demonstrated that POR*28 affects CYP3A4 activity in a substrate-specific manner [34,35]. Several PK studies demonstrated that POR*28 is related to increased CYP3A activity. The study of Oneda et al. [36], which investigated CYP3A in vivo activity using midazolam, showed that POR*28/*28 was related to a 1.6-fold increase in hepatic CYP3A activity. Yang et al. [37] also showed that POR*28 was associated with increased hepatic CYP3A activity. In line with previous findings, our results regarding increased CYP3A activity might be explained by the effects of POR*28.
Several studies have reported that decreased exposure to TAC within a week after transplantation was associated with acute organ rejection. Kuypers et al. [38] reported that patients with an area under the concentration curve of 0–12 h (AUC(0–12)) below 200 ng·h/mL had a higher risk of acute rejection when compared with those with a higher AUC(0–12). Borobia et al. [39] also showed that patients with acute organ rejection had lower TAC trough concentrations than those without acute organ rejection. Our meta-analysis demonstrating that patients carrying the POR*28 allele had decreased TAC concentrations indicates POR*28 is an important factor in predicting acute organ rejection.
According to the subgroup analysis in this meta-analysis, POR*28 effects on the TAC concentration varied by CYP3A5 expression status, which is consistent with previous studies. For example, according to Jonge et al. [18], CYP3A5 expressers carrying the POR*28 allele required an approximately 25% higher TAC dose than CYP3A5 expressers with POR*1/*1, although the POR*28 allele did not affect TAC doses in CYP3A5 non-expressers. Gijsen et al. [40] reported that, in CYP3A5 expressers, patients with the POR*28 allele had an approximately 20% lower TAC concentration-to-dose ratio than those with POR*1/*1. However, the POR*28 polymorphism had no effect on the TAC concentration/dose ratio in CYP3A5 non-expressers. This can be explained by the role of POR, which provides electrons and enhances CYP activity.
Ethnicity may affect the expression of POR and thereby TAC metabolism. As the minor allele frequency of POR*28 was 20.0% in African Americans, 28.6% in Caucasians, and 38.9% in Asians [41], Asians are thought to be more affected by POR*28. Unfortunately, we could not compare the POR*28 effects by ethnicity, due to the small number of studies in non-Asian populations. Further studies are needed.
Our findings should be interpreted considering the following limitations. First, only six retrospective studies were included. Second, some heterogeneity existed, possibly due to the difference in the analytic methods used to determine concentrations and target concentrations. Last, although we used standardized trough concentrations after considering weight and dose, we could not adjust several factors (e.g., concurrent drugs), which can affect TAC concentrations, due to the lack of individual data.
Nevertheless, our meta-analysis demonstrated that the POR*28 polymorphism affects the TAC standardized trough concentration during the early post-transplantation period in adult renal transplant recipients, especially CYP3A5 expressers. POR and CYP3A5 genotyping might help to adjust appropriate TAC doses to reach target trough concentrations, leading to better treatment outcomes.

Author Contributions

Conceptualization, D.-H.L., J.Y. and H.-S.G.; methodology, D.-H.L., H.-Y.Y., J.Y. and H.-S.G.; formal analysis, D.-H.L., H.L. and H.-Y.Y.; investigation, D.-H.L., H.L., H.-Y.Y., J.Y. and H.-S.G.; writing—original draft preparation, D.-H.L., J.Y. and H.-S.G.; writing—review and editing, J.Y. and H.-S.G.; supervision, J.Y. and H.-S.G. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Ethical review and approval were waived for this study due to the nature of the systematic review article.

Informed Consent Statement

Patient consent was waived due to the nature of the systematic review article.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Lesley, S. Tacrolimus, A further update of its use in the management of organ transplantation. Drugs 2003, 63, 1247–1297. [Google Scholar]
  2. Felipe, C.R.; Silva, H.T.; Machado, P.G.; Garcia, R.; da Silva Moreira, S.R.; Pestana, J.O. The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. Clin. Transplant. 2002, 16, 262–272. [Google Scholar] [CrossRef]
  3. Taylor, A.L.; Watson, C.J.; Bradley, J.A. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit. Rev. Oncol./Hematol. 2005, 56, 23–46. [Google Scholar] [CrossRef]
  4. Venkataramanan, R.; Swaminathan, A.; Prasad, T.; Jain, A.; Zuckerman, S.; Warty, V.; McMichael, J.; Lever, J.; Burckart, G.; Starzl, T. Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet. 1995, 29, 404–430. [Google Scholar] [CrossRef] [PubMed]
  5. Laskow, D.A.; Vincenti, F.; Neylan, J.F.; Mendez, R.; Matas, A.J. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: A Report of the United States Multicenter FK506 Kidney Transplant Group1. Transplantation 1996, 62, 900–905. [Google Scholar] [CrossRef] [PubMed]
  6. Anglicheau, D.; Verstuyft, C.; Laurent-Puig, P.; Becquemont, L.; Schlageter, M.-H.; Cassinat, B.; Beaune, P.; Legendre, C.; Thervet, E. Association of the Multidrug Resistance-1 Gene Single-Nucleotide Polymorphisms with the Tacrolimus Dose Requirements in Renal Transplant Recipients. J. Am. Soc. Nephrol. 2003, 14, 1889–1896. [Google Scholar] [CrossRef] [Green Version]
  7. Hustert, E.; Haberl, M.; Burk, O.; Wolbold, R.; He, Y.-Q.; Klein, K.; Nuessler, A.C.; Neuhaus, P.; Klattig, J.; Eiselt, R.; et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001, 11, 773–779. [Google Scholar] [CrossRef]
  8. Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Schuetz, E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 2001, 27, 383–391. [Google Scholar] [CrossRef] [Green Version]
  9. Mourad, M.; Mourad, G.; Wallemacq, P.; Garrigue, V.; Van Bellingen, C.; Van Kerckhove, V.; De Meyer, M.; Malaise, J.; Eddour, D.C.; Lison, D.; et al. Sirolimus and Tacrolimus Trough Concentrations and Dose Requirements after Kidney Transplantation in Relation to CYP3A5 and MDR1 Polymorphisms and Steroids. Transplantation 2005, 80, 977–984. [Google Scholar] [CrossRef] [PubMed]
  10. Thervet, E.; Anglicheau, D.; King, B.; Schlageter, M.H.; Cassinat, B.; Beaune, P.; Christophe, L.; Daly, A.K. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12. Transplantation 2003, 76, 1233–1235. [Google Scholar] [CrossRef] [PubMed]
  11. Zheng, H.; Webber, S.; Zeevi, A.; Schuetz, E.; Zhang, J.; Bowman, P.; Boyle, G.; Law, Y.; Miller, S.; Lamba, J.; et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant. 2003, 3, 477–483. [Google Scholar] [CrossRef]
  12. Goto, M.; Masuda, S.; Kiuchi, T.; Ogura, Y.; Oike, F.; Okuda, M.; Tanaka, K.; Inui, K.-I. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 2004, 14, 471–478. [Google Scholar] [CrossRef] [PubMed]
  13. Hubbard, P.A.; Shen, A.L.; Paschke, R.; Kasper, C.B.; Kim, J.J.P. NADPH-cytochrome P450 oxidoreductase: Structural basis for hydride and electron transfer. J. Biol. Chem. 2001, 276, 29163–29170. [Google Scholar] [CrossRef] [Green Version]
  14. Masters, B.S.S. The journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthases. Biochem. Biophys. Res. Commun. 2005, 338, 507–519. [Google Scholar] [CrossRef]
  15. Agrawal, V.; Huang, N.; Miller, W.L. Pharmacogenetics of P450 oxidoreductase: Effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharm. Genom. 2008, 18, 569–576. [Google Scholar] [CrossRef] [PubMed]
  16. Lunde, I.; Bremer, S.; Midtvedt, K.; Mohebi, B.; Dahl, M.; Bergan, S.; Åsberg, A.; Christensen, H. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur. J. Clin. Pharmacol. 2004, 70, 685–693. [Google Scholar] [CrossRef] [Green Version]
  17. Madsen, M.J.; Bergmann, T.K.; Brøsen, K.; Thiesson, H.C. The pharmacogenetics of tacrolimus in corticosteroid-sparse pediatric and adult kidney transplant recipients. Drugs R&D 2017, 17, 279–286. [Google Scholar]
  18. De Jonge, H.; Metalidis, C.; Naesens, M.; Lambrechts, D.; Kuypers, D.R. The P450 oxidoreductase* 28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 2011, 12, 1281–1291. [Google Scholar] [CrossRef]
  19. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef]
  20. Wells, G.A.; Shea, B.; O’Connell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. 2002. Available online: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed on 4 January 2022).
  21. Wan, X.; Wang, W.; Liu, J.; Tong, T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol. 2014, 14, 135. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Higgins, J.P.; White, I.R.; Anzures-Cabrera, J. Meta-analysis of skewed data: Combining results reported on log-transformed or raw scales. Stat. Med. 2008, 27, 6072–6092. [Google Scholar] [CrossRef] [Green Version]
  23. Higgins, J.P.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21, 1539–1558. [Google Scholar] [CrossRef] [PubMed]
  24. Begg, C.B.; Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50, 1088–1101. [Google Scholar] [CrossRef] [PubMed]
  25. Egger, M.; Smith, G.D.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315, 629–634. [Google Scholar] [CrossRef] [Green Version]
  26. Elens, L.; Hesselink, D.A.; Bouamar, R.; Budde, K.; De Fijter, J.W.; De Meyer, M.; Mourad, M.; Kuypers, D.R.; Haufroid, V.; Van Gelder, T.; et al. Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant Patients. Ther. Drug Monit. 2014, 36, 71–79. [Google Scholar] [CrossRef]
  27. Kurzawski, M.; Malinowski, D.; Dziewanowski, K.; Drozdzik, M. Impact of PPARA and POR polymorphisms on tacrolimus pharmacokinetics and new-onset diabetes in kidney transplant recipients. Pharm. Genom. 2014, 24, 397–400. [Google Scholar] [CrossRef]
  28. Li, C.-J.; Li, L.; Lin, L.; Jiang, H.-X.; Zhong, Z.-Y.; Li, W.-M.; Zhang, Y.-J.; Zheng, P.; Tan, X.-H.; Zhou, L. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR Genetic Polymorphisms on Tacrolimus Metabolism in Chinese Renal Transplant Recipients. PLoS ONE 2014, 9, e86206. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Zhang, J.J.; Liu, S.B.; Xue, L.; Ding, X.L.; Zhang, H.; Miao, L.Y. The genetic polymorphisms of POR* 28 and CYP3A5* 3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Int. J. Clin. Pharmacol. Ther. 2015, 53, 728–736. [Google Scholar] [CrossRef]
  30. Liu, S.; Chen, R.X.; Li, J.; Zhang, Y.; Wang, X.D.; Fu, Q.; Chen, L.; Liu, X.; Huang, H.; Huang, M.; et al. The POR rs1057868–rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients. Acta Pharmacol. Sin. 2016, 37, 1251–1258. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Phupradit, A.; Vadcharavivad, S.; Ingsathit, A.; Kantachuvesiri, S.; Areepium, N.; Sra-Ium, S.; Auamnoy, T.; Sukasem, C.; Sumethkul, V.; Kitiyakara, C. Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation. Ther. Drug Monit. 2018, 40, 549–557. [Google Scholar] [CrossRef] [PubMed]
  32. Huang, N.; Agrawal, V.; Giacomini, K.M.; Miller, W.L. Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc. Natl. Acad. Sci. USA 2008, 105, 1733–1738. [Google Scholar] [CrossRef] [Green Version]
  33. Huang, N.; Pandey, A.V.; Agrawal, V.; Reardon, W.; Lapunzina, P.D.; Mowat, D.; Jabs, E.W.; Van Vliet, G.; Sack, J.; Flück, C.E.; et al. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am. J. Hum. Genet. 2005, 76, 729–749. [Google Scholar] [CrossRef] [Green Version]
  34. Fluck, C.E.; Mullis, P.E.; Pandey, A.V. Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism. Biochem. Biophys. Res. Commun. 2010, 401, 149–153. [Google Scholar] [CrossRef] [PubMed]
  35. Agrawal, V.; Choi, J.H.; Giacomini, K.M.; Miller, W.L. Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharm. Genom. 2010, 20, 611–618. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Oneda, B.; Crettol, S.; Sirot, E.J.; Bochud, M.; Ansermot, N.; Eap, C.B. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharm. Genom. 2009, 19, 877–883. [Google Scholar] [CrossRef] [PubMed]
  37. Yang, G.; Fu, Z.; Chen, X.; Yuan, H.; Yang, H.; Huang, Y.; Ouyang, D.; Tan, Z.; Tan, H.; Huang, Z.; et al. Effects of the CYP Oxidoreductase Ala503Val Polymorphism on CYP3A Activity In Vivo: A Randomized, Open-Label, Crossover Study in Healthy Chinese Men. Clin. Ther. 2011, 33, 2060–2070. [Google Scholar] [CrossRef] [PubMed]
  38. Kuypers, D.R.; Claes, K.; Evenepoel, P.; Maes, B.; Vanrenterghem, Y. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin. Pharmacol. Ther. 2004, 75, 434–447. [Google Scholar] [CrossRef] [PubMed]
  39. Borobia, A.M.; Romero, I.; Jimenez, C.; Gil, F.; Ramírez, E.; De Gracia, R.; Escuin, F.; González, E.; Sansuán, A.J.C. Trough Tacrolimus Concentrations in the First Week After Kidney Transplantation Are Related to Acute Rejection. Ther. Drug Monit. 2009, 31, 436–442. [Google Scholar] [CrossRef]
  40. Gijsen, V.M.; van Schaik, R.H.; Soldin, O.P.; Soldin, S.J.; Nulman, I.; Koren, G.; de Wildt, S.N. P450 oxidoreductase* 28 (POR* 28) and tacrolimus disposition in pediatric kidney transplant recipients—A pilot study. Ther. Drug Monit. 2014, 36, 152–158. [Google Scholar] [CrossRef] [PubMed]
  41. Sherry, S.T.; Ward, M.H.; Kholodov, M.; Baker, J.; Phan, L.; Smigielski, E.M.; Sirotkin, K. dbSNP: The NCBI database of genetic variation. Nucleic Acids Res. 2001, 29, 308–311. [Google Scholar] [CrossRef] [Green Version]
Pharmaceutics 14 00261 g001 550
Figure 1. A flow diagram of study selection.
Figure 1. A flow diagram of study selection.
Pharmaceutics 14 00261 g001
Pharmaceutics 14 00261 g002 550
Figure 2. A forest plot showing the association between POR*28 carriers and standardized trough concentration (ng/mL per mg/kg) of tacrolimus.
Figure 2. A forest plot showing the association between POR*28 carriers and standardized trough concentration (ng/mL per mg/kg) of tacrolimus.
Pharmaceutics 14 00261 g002
Pharmaceutics 14 00261 g003 550
Figure 3. A funnel plot showing the association between POR*28 carriers and standardized trough concentration (ng/mL per mg/kg) of tacrolimus. SE: standard error, MD: mean difference.
Figure 3. A funnel plot showing the association between POR*28 carriers and standardized trough concentration (ng/mL per mg/kg) of tacrolimus. SE: standard error, MD: mean difference.
Pharmaceutics 14 00261 g003
Pharmaceutics 14 00261 g004 550
Figure 4. Forest plots with CYP3A5 expressing and CYP3A5 non-expressing subgroups showing the association between POR*28 carriers and standardized trough concentration (ng/mL per mg/kg) of tacrolimus. (a) CYP3A5 expressers; (b) CYP3A5 non-expressers.
Figure 4. Forest plots with CYP3A5 expressing and CYP3A5 non-expressing subgroups showing the association between POR*28 carriers and standardized trough concentration (ng/mL per mg/kg) of tacrolimus. (a) CYP3A5 expressers; (b) CYP3A5 non-expressers.
Pharmaceutics 14 00261 g004
Table
Table 1. Search strategy.
Table 1. Search strategy.
NoSearch TermPubMedWeb of ScienceEmbase
#1(tacrolimus) OR (FK506) OR (FK-506) OR (calcineurin inhibitor) OR (Prograf) OR (immunosuppress*)481,508153,419391,339
#2(kidney transplant*) OR (kidney graft*) OR (kidney allograft*) OR (renal transplant*) OR (renal graft*) OR (renal allograft*)190,248202,994324,655
#3#1 and #248,44831,89278,405
#4(POR) OR (P450 oxidoreductase) OR (cytochrome P450 oxidoreductase) OR (CYPOR)138,66316,91070,583
#5(polymorph*) OR (variant*) OR (mutation*) OR (genotyp*) OR (phenotyp*) OR (haplotyp*) OR (SNP) OR (rs1057868) OR (Ala503Val) OR (A503V)2,146,9092,144,5832,821,213
#6#4 and #525,46817943279
#7#3 and #64605373
Table
Table 2. The characteristics of included studies.
Table 2. The characteristics of included studies.
First Author, YearEthnic BackgroundN (Male %)Age, Year (SD)Weight, kg (SD)POR*28 Allele Frequency (%)Post-Transplantation DayInitial DoseTarget Trough Level, ng/mLCoadministrationGenotyping MethodsQuantification MethodsNOS
Elens et al., 2014 [26]Caucasian, Asian, Africa-American, Others127 * (60.2)49.5 (15.3) 72.6 (16.6)22.110NA5~15MMF or azathioprine, corticosteroidsTaqMan assayMEIA9
Kurzawski et al., 2014 [27]Caucasian241 (55.6)45.8 (12.4)73.2 (13.9)26.47100 ng/kg/day10~15MMF, corticosteroidsTaqMan assayCMIA9
Li et al., 2014 [28]Asian240 (67.1)41.0 (12.2)57.9 (10.1)35.66~8100 ng/kg, bid9~14MMF, steroidsSNaPshot assayMEIA7
Zhang et al., 2015 [29]Asian83 (72.3)40.4 (11.3)62.0 (9.4)39.87NA10~15MMF, steroidsPCR-RFLPEmit 2000 Tacrolimus assay9
Liu et al., 2016 [30]Asian154 (NA)40.0 (10.9)59.8 (10.7)34.1750~75 ng/kg, bid5~8MMF, prednisolonePCR-RFLPMEIA8
Phupradit et al., 2018 [31]Asian216 (61.1)43.0 (14.6)57.1 (11.3)32.47100 ng/kg/day4~8Mycophenolic acid, corticosteroids or basiliximabTaqMan assayCMIA9
bid: twice a day; CMIA: chemiluminescent microparticle immunoassay; MEIA: microparticle enzyme immunoassay; MMF: mycophenolate mofetil; NA: not available; NOS: Newcastle–Ottawa score; PCR–RFLP: polymerase chain reaction–restriction fragment length polymorphism; SD: standard deviation. * Of the total population of 184, only 127 blood samples were obtained on day 10.
Table
Table 3. A sensitivity analysis of the association between POR*28 carriers and standardized trough concentration (ng/mL per mg/kg) of tacrolimus by sequentially excluding each study.
Table 3. A sensitivity analysis of the association between POR*28 carriers and standardized trough concentration (ng/mL per mg/kg) of tacrolimus by sequentially excluding each study.
Excluded StudyHeterogeneity I2 (%)Statistical ModelMean Difference [95% CI]
None55Random−11.67 [−14.16, −9.19]
Elens et al., 2014 [26]62Random−8.68 [−15.95, −1.42]
Kurzawski et al., 2014 [27]53Random−9.51 [−16.32, −2.70]
Li et al., 2014 [28]52Random−9.61 [−16.04, −3.17]
Zhang et al., 2015 [29]54Random−6.97 [−13.17, −0.76]
Liu et al., 2016 [30]29Fixed−5.38 [−11.17, 0.40]
Phupradit et al., 2018 [31]58Random−8.84 [−16.59, −1.09]
CI: confidence interval.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lee, D.-H.; Lee, H.; Yoon, H.-Y.; Yee, J.; Gwak, H.-S. Association of P450 Oxidoreductase Gene Polymorphism with Tacrolimus Pharmacokinetics in Renal Transplant Recipients: A Systematic Review and Meta-Analysis. Pharmaceutics 2022, 14, 261. https://doi.org/10.3390/pharmaceutics14020261

AMA Style

Lee D-H, Lee H, Yoon H-Y, Yee J, Gwak H-S. Association of P450 Oxidoreductase Gene Polymorphism with Tacrolimus Pharmacokinetics in Renal Transplant Recipients: A Systematic Review and Meta-Analysis. Pharmaceutics. 2022; 14(2):261. https://doi.org/10.3390/pharmaceutics14020261

Chicago/Turabian Style

Lee, Da-Hoon, Hana Lee, Ha-Young Yoon, Jeong Yee, and Hye-Sun Gwak. 2022. "Association of P450 Oxidoreductase Gene Polymorphism with Tacrolimus Pharmacokinetics in Renal Transplant Recipients: A Systematic Review and Meta-Analysis" Pharmaceutics 14, no. 2: 261. https://doi.org/10.3390/pharmaceutics14020261

APA Style

Lee, D. -H., Lee, H., Yoon, H. -Y., Yee, J., & Gwak, H. -S. (2022). Association of P450 Oxidoreductase Gene Polymorphism with Tacrolimus Pharmacokinetics in Renal Transplant Recipients: A Systematic Review and Meta-Analysis. Pharmaceutics, 14(2), 261. https://doi.org/10.3390/pharmaceutics14020261

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop